- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 10,80 € / 11,00 € |
| Spread | +1,85% |
| Schluss Vortag | 10,50 € |
| Gehandelte Stücke | 8.698 |
| Tagesvolumen Vortag | 4.718,4 € |
| Tagestief 10,50 € Tageshoch 10,90 € | |
| 52W-Tief 4,18 € 52W-Hoch 13,70 € | |
| Jahrestief 4,28 € Jahreshoch 13,70 € | |
| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | -285,82 $ |
| Jahresüberschuss in Mio. | -287,86 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -3,07 $ |
| Gewinnrendite | - |
| Umsatzrendite | - |
| Return on Investment | -136,85% |
| Marktkapitalisierung in Mio. | 1.551 $ |
| KGV (Kurs/Gewinn) | -2,25 |
| KBV (Kurs/Buchwert) | - |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | -25,12% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 10,60 € | +3,92% | 10,20 € | 19:30 | |
| Frankfurt | 10,30 € | -5,50% | 10,90 € | 09:55 | |
| Gettex | 10,90 € | +3,81% | 10,50 € | 21:43 | |
| Hamburg | 10,20 € | +6,81% | 9,55 € | 08:19 | |
| Hannover | 10,20 € | +6,81% | 9,55 € | 08:04 | |
| L&S RT | 11,00 € | +5,26% | 10,45 € | 22:11 | |
| München | 10,60 € | +4,95% | 10,10 € | 08:08 | |
| Nasdaq | 12,28 $ | +3,98% | 11,81 $ | 21:00 | |
| NYSE | 12,305 $ | +4,24% | 11,805 $ | 20:59 | |
| NYSE American | 12,10 $ | +2,37% | 11,82 $ | 20:33 | |
| Quotrix | 10,70 € | +7,54% | 9,95 € | 13:17 | |
| Stuttgart | 10,90 € | +4,81% | 10,40 € | 21:55 | |
| Tradegate BSX | 10,80 € | +1,89% | 10,60 € | 20:28 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 28.10.26 | 10,90 | 93 T |
| 27.10.26 | 10,50 | 4.718 |
| 26.10.26 | 9,95 | 150 |
| 23.10.26 | 9,95 | 4.977 |
| 22.10.26 | 10,40 | 8.384 |
| 21.10.26 | 10,60 | 11.599 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 10,60 € | +2,83% |
| 1 Monat | 11,70 € | -6,84% |
| 6 Monate | 7,25 € | +50,34% |
| 1 Jahr | 5,65 € | +92,92% |
| 5 Jahre | 34,40 € | -68,31% |
| Marktkapitalisierung | 1,55 Mrd. $ |
| Streubesitz | 23,12% |
| Währung | USD |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Medizinische Einrichtungen |
| Aktientyp | ADR |
| +8,78% | Deep Track Capital, LP |
| +7,73% | RTW INVESTMENTS, LLC |
| +3,61% | TANG CAPITAL MANAGEMENT LLC |
| +3,27% | ARK Genomic Revolution ETF |
| +3,23% | Two Sigma Investments LLC |
| +3,13% | Marshall Wace Asset Management Ltd |
| +2,49% | ARK Investment Management LLC |
| +1,89% | Point72 Asset Management, L.P. |
| +1,62% | Logos Global Management LP |
| +1,49% | Eagle Health Investments LP |
| +1,46% | Bank of America Corp |
| +1,45% | Dafna Capital Management LLC |
| +1,28% | NEXTBio Capital Management LP |
| +1,26% | BIT Global Technology Leaders R-I |
| +1,18% | Kalehua Capital Management LLC |
| +1,07% | UBS Group AG |
| +1,03% | Aisling Capital Management LP |
| +1,03% | Renaissance Technologies Corp |
| +0,92% | Candriam Luxembourg S.C.A. |
| +0,78% | Woodline Partners LP |
| +0,73% | Citadel Advisors Llc |
| +0,72% | Jefferies Financial Group Inc |
| +0,64% | iShares Biotechnology ETF |
| +0,35% | AdvisorShares Psychedelics ETF |
| +0,33% | TEQ - Disruptive Technologies - I-II |
| +0,21% | L&G Healthcare Tech & Innovt ETF USD Acc |
| +0,2% | ARK Genomic Revolution ETF A USD Acc |
| +0,19% | T. Rowe Price Integrated US Sm Gr Eq |
| +0,16% | SEB Nordamerikafond Småbolag |
| +0,13% | ALPS Medical Breakthroughs ETF |
| +0,13% | Royce Small-Cap Growth Growth Svc |
| +0,12% | HealthInvest Sustainable Healthcare E |
| +0,11% | Goldman Sachs Small Cap Growth P |
| +0,11% | Premier Miton Diversified GrB Inc |
| +0,11% | TEQ- Disruptive Tech In I-III |
| +0,08% | Adara Smaller Companies |
| +0,08% | iShares Nasdaq US Biotech ETF USD Acc |
| +0,08% | BIT Defensive Growth S |
| +0,07% | Undly L&G Future World UK Eq Idx Fd |
| +0,07% | State Street® SPDR® S&P® Intl Sm Cp ETF |
| +69,256% | Institutionelle Aktionäre |
| +7,624% | Insider Aktionäre |
| +23,12% | Streubesitz |
https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Dosing-Complete-for-All-Participants-in-Part-A-of-Phase-3-COMP005-Trial-of-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx
Zahlen für Q3/24
- Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025
- Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%
Vorbörslich -30% auf 4,25$
Zahlen für Q2/23
- 16,07 Mio. neue Aktien zu je 7,78$ = 125 Mio. $ PP
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-announces-second-quarter-2023-financial-results
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-announces-285-million-private-placement